Form 4: Lyell Immunopharma VP Sells Shares for Tax Obligations

Lyell Immunopharma's VP, Corporate Controller, Veronica Sanchez Bulis, sold 239 shares of common stock to cover tax withholding obligations from vested restricted stock units.

Summary

• Veronica Sanchez Bulis, the VP, Corporate Controller of Lyell Immunopharma, Inc. (LYEL), reported a transaction on November 10, 2025.
• The transaction involved the sale of 239 shares of Lyell Immunopharma Common Stock.
• The shares were sold at a weighted average price of $16.1 per share, with prices ranging from $16.08 to $16.11.
• The sale was an automatic transaction to cover tax withholding obligations arising from the settlement of vested restricted stock units.
• Following this transaction, Veronica Sanchez Bulis directly beneficially owns 9,213 shares of Common Stock.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged plan for the purchase or sale of equity securities.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned sale to cover tax obligations upon RSU vesting, which is a neutral event for company sentiment and does not indicate a discretionary sale based on company performance or outlook.

Future Outlook

NA

Industry Context

This filing details a routine insider transaction, specifically a sale of shares by a corporate officer to cover tax obligations upon the vesting of restricted stock units. Such transactions are common across all industries for executives receiving equity compensation and do not typically reflect broader industry trends or specific company performance outlooks.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in management's confidence or company fundamentals.

Key Dates

Recommendation

The transaction reported is a routine sale of shares by an executive to cover tax withholding obligations upon the vesting of restricted stock units. This is a common and often pre-planned event (indicated by the 10b5-1 box) and does not reflect a discretionary decision to sell based on company performance or outlook. Therefore, it should not significantly influence an investment decision, and a 'hold' recommendation is appropriate as this event is neutral to the company's fundamental value.

Keywords

Lyell Immunopharma, LYEL, Form 4, insider transaction, stock sale, tax withholding, restricted stock units, corporate controller, beneficial ownership